ReviewInternational journal of molecular sciences2024
MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2025Pooled it
- Review
- Recent Advances in Non-Invasive Blood Markers for Intraductal Papillary Mucinous Neoplasm Grading.Oncology research · 2026Review
- Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy.Oncology research · 2026Review
- Pancreatic cancer in 2025: Have we found a solution?World journal of gastroenterology · 2025Review
- Unraveling the therapeutic landscape of miRNAs in pancreatic cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.Journal of nanobiotechnology · 2025Review
- A Pilot Study of Exploring miRNA-Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis.Diagnostics (Basel, Switzerland) · 2025Article
- Circulating miRNAs as Non-Invasive Biomarkers in Pancreatic Cancer: A Two-Phase Plasma-Based Study.Journal of clinical medicine · 2025Article
- The Evolving Landscape of microRNAs in Cholangiocarcinoma and Pancreatic Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- 4D-printed microdevices for spatiotemporal detection of ctDNA and miRNA in pancreatic cancer: an in-depth review.Medical oncology (Northwood, London, England) · 2025Review
- Review
- Machine learning-based construction of a programmed cell death-related model reveals prognosis and immune infiltration in pancreatic adenocarcinoma patients.Scientific reports · 2025Article
- Article
- Role of noncoding RNA and protein interaction in pancreatic cancer.Chinese medical journal · 2025Review
- Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management.Journal of clinical medicine · 2025Review
- Target and Gene-Based Therapeutic Strategies against Pancreatic Cancer: Current and Future Prospects.Current gene therapy · 2025Review
- Baicalein inhibits DDX60 to suppress pancreatic cancer growth and regulate the tumor microenvironment.American journal of translational research · 2025Article
- Extracellular derived-exosomal micrornas in pancreatic cancer: investigating their diagnostic importance and potential targets for the prevention and treatment in pancreatic cancer.Frontiers in oncology · 2025Review
- The place of advanced machine learning techniques in building pancreatic adenocarcinoma survival and recurrence prognosis models.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains a formidable malignancy characterized by high mortality rates, primarily attributable to late-stage diagnosis and a dearth of effective therapeutic interventions. The identification of reliable biomarkers holds paramount importance in enhancing early detection, prognostic evaluation, and targeted treatment modalities. Small non-coding RNAs, particularly microRNAs, have emerged as promising candidates for pancreatic cancer biomarkers in recent years. In this review, we delve into the evolving role of cellular and circulating miRNAs, including exosomal miRNAs, in the diagnosis, prognosis, and therapeutic targeting of pancreatic cancer. Drawing upon the latest research advancements in omics data-driven biomarker discovery, we also perform a case study using public datasets and address commonly identified research discrepancies, challenges, and limitations. Lastly, we discuss analytical approaches that integrate multimodal analyses incorporating clinical and molecular features, presenting new insights into identifying robust miRNA-centric biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.